CYTOMEGALOVIRUS INDUCED UP-REGULATION OF LFA-3 (CD58) AND ICAM-1(CD54) IS A DIRECT VIRAL EFFECT THAT IS NOT PREVENTED BY GANCICLOVIR OR FOSCARNET TREATMENT1
- 27 October 1996
- journal article
- immunobiology
- Published by Wolters Kluwer Health in Transplantation
- Vol. 62 (8) , 1102-1108
- https://doi.org/10.1097/00007890-199610270-00014
Abstract
Cytomegalovirus (CMV) is a major pathogen in transplant recipients and AIDS patients, and the virus may also play a role in allograft rejection. Previous work from this laboratory demonstrated increased cell surface expression of the adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) following CMV infection in vitro. We investigated whether the induction of adhesion molecules by CMV was a direct viral effect or secondary to cytokine induction. Cytokines known to up-regulate ICAM-1, such as TNFα or IL-1β, were not detected in the supernatants of infected fibroblasts, and neutralizing antibodies against these cytokines did not abrogate the induction of either ICAM-1 or LFA-3 by CMV. Infected cell supernatants had increased levels of IL-6, IL-8 and IFNβ however, the addition of recombinant forms of these cytokines did not affect adhesion molecule expression. Neither virusfree infected cell supernatants nor UV-inactivated virus up-regulated adhesion molecules, demonstrating that the induction of ICAM-1 and LFA-3 by CMV was a direct effect requiring infectious virus. Effective antiviral treatment with ganciclovir or foscarnet accentuated rather than abrogated the up-regulation of adhesion molecules, suggesting that CMV immediate early/ early gene expression, which is not blocked by such treatment, was responsible for the adhesion molecule induction. Thus, despite effective antiviral therapy in the transplant recipient, CMV infected cells may continue to provide a focus of proinflammatory activity, which could contribute to immunopathology and/or accentuate graft rejection or graft-versus-host disease in vivo.Keywords
This publication has 38 references indexed in Scilit:
- INHIBITION OF TRANSPLANT REJECTION BY PRETREATMENT OF XENOGENEIC PANCREATIC ISLET CELLS WITH ANTI-ICAM-1 ANTIBODIESTransplantation, 1994
- Human cytomegalovirus late protein encoded by ie2: a trans-activator as well as a repressor of gene expressionJournal of General Virology, 1994
- Cytomegalovirus infection and allospecific cytotoxic activity of graft‐infiltrating cells after heart transplantationJournal of Medical Virology, 1994
- Influence of Epstein-Barr Virus Encoded Latent Membrane Protein 1 on the Expression of CD23 Antigen, ICAM-1 and LFA-3 in Hodgkin and Reed-Sternberg Cells. A Morphometric AnalysisLeukemia & Lymphoma, 1993
- PRETRANSPLANT AND POSTTRANSPLANT ANTIBODIES IN HUMAN CORNEAL TRANSPLANTATIONTransplantation, 1992
- Cytomegalovirus Infection Persists in the Liver Graft in the Vanishing Bile Duct SyndromeHepatology, 1992
- beta2 Microglobulin on the envelope of urinary cytomegalovirus is not associated with host class I human leukocyte antigen chainJournal of General Virology, 1992
- Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1Science, 1992
- TREATMENT OF INVASIVE CYTOMEGALOVIRUS DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS WITH GANCICLOVIRTransplantation, 1991
- The Effect of Human Cytomegalovirus on the Production and Biologic Action of Interleukin-lThe Journal of Infectious Diseases, 1990